Traditional transfusion practices are changing by Holcomb, John B
Th  e data presented by Schochl and colleagues will be 
seen as intriguing, important, innovative, and contro-
versial [1]. Th   is paper builds on work by Dr Detmer Fries, 
published in a swine injury model in 2006 [2,3]. However, 
as with all retrospective studies, caution must be exer-
cised before widespread adoption. Th  e usual concerns 
apply as there is no control group, the data supporting 
the thromboelastometry goal-directed algorithm are not 
presented, and the risks of using and combining ﬁ  brino-
gen concentrates and plasma complex concen  trates 
(PCCs) in trauma patients are unknown. Preclinical and 
clinical evidence to answer these questions is lacking and 
should be investigated.
With regards to the study by Schochl and colleagues, I 
am concerned with the comparison of mortality rates in 
the small numbers of seriously injured patients collected 
over 5 years to that predicted by the trauma injury 
severity score (TRISS) and by the revised injury severity 
classiﬁ  cation (RISC) score. It is very easy for such small 
data sets to suﬀ  er signiﬁ  cant statistical problems when 
attempting to match injuries and initial physiology. It 
would have been preferable to at least construct a before 
and after design. Several questions are apparent: when 
the thromboelastometry was repeated, did the test results 
change (improve?) after transfusion of the proscribed 
agent? What was the timing of the ﬁ  brinogen and PCC 
concentrates in relation to red blood cells (RBCs)? How 
often was the ﬁ  brinogen or PCC given before the RBCs? 
How did mortality change over time, as the authors 
became more comfortable with their alternative resusci-
tation strategy?
Despite these and many more questions, I sincerely 
congratulate the authors on forging ahead and intro  ducing 
a novel resuscitation approach. Th   e issues inherent in this 
retrospective study (and in every one of the recently 
published retrospective transfusion studies, including ours 
[4]) are signiﬁ  cant and will only be resolved when pros-
pective studies are ﬁ   nally performed. As an aside, this 
standard comment leads me to wonder why we must have 
level I data to change traditional practice, when the current 
transfusion traditions are based on small, uncontrolled, 
rarely read, retrospective studies utilizing blood products 
no longer available. Tradition is recognized as the hardest 
thing to change, and the recent and now numerous 
transfusion studies in seriously injured patients are 
arguably leading the way in a wholesale revolution in 
transfusion medicine. It seems that physiology is starting 
to take precedence over tradition in this area, and other 
specialties are taking notice.
We now recognize that fully one-third of transfused 
patients are coagulopathic. For years, in seriously injured 
trauma patients suﬀ   ering hemorrhagic shock, we ﬁ  rst 
gave multiple varieties of salt solutions, followed by 
RBCs. Th   ere was an ongoing controversy about crystal-
loid versus colloid; these resuscitation ﬂ  uids  increase 
coagulation problems and neither increase oxygen 
delivery. Only after liters of these ﬂ  uids were transfused 
were components that both increased intravascular 
volume and helped reverse coagulopathy ﬁ  nally delivered. 
Now, many centers are giving early and increased 
amounts of plasma proteins and platelets. At our center 
we more frequently give plasma before RBCs in our 
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Schochl and co-authors have described a 5-year 
retrospective study that outlines a novel, important 
and controversial transfusion concept in seriously 
injured trauma patients. Traditionally, clinicians have 
been taught to use a serial approach, resuscitating 
hypovolemic trauma patients with a form of crystalloid 
or colloid, followed by red blood cells (RBCs), then 
fresh frozen plasma (FFP), and lastly platelets. The 
data supporting this widely accepted approach 
are remarkably weak. Conversely, Schochl and 
colleagues, in an innovative, retrospective study, 
describe the use of fi  brinogen concentrate, plasma 
complex concentrate, RBCs, FFP, and platelets driven 
by a thromboelastometry-based algorithm. Finally, it 
appears that transfusion therapy is becoming driven by 
physiology.
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shock. Anecdotally, this change in practice has been 
associated with less bleeding, improved survival, 
decreased edema and lowered multiple organ failure 
rates. Th  e mechanism accounting for these clinical 
observations remains to be elucidated [5,6]. We feel that 
many of these products not only replace coagulation 
factors, facilitating early cessation of bleeding, and 
provide eﬀ  ective volume resuscitation, but more impor-
tantly stabilize the endothelium, reverse the early 
coagulopathy of trauma, reverse endothelial permeability, 
decrease edema and repair the endothelium, thus 
preventing early onset of multiple organ failure related to 
resuscitation injury. Th   e thousands of proteins present in 
platelets and plasma certainly ‘do more than’ just replace 
the few coagulation proteins we commonly measure.
Th  e transfusion method of Schochl and colleagues 
appears to be more physiologic and data driven when 
compared to the tradition-motivated approach to 
resuscitation of the severely injured trauma patient in 
hemorrhagic shock. More studies like this will soon see 
the light of publication and form the basis for a revolution 
in transfusion therapy over the next decade. I think that 
commercial entities should take note, as their approach 
will certainly open new markets and opportunities.
Current blood banks are largely focused on logistical 
issues of shelf life, avoiding disease transmission, and the 
immunologic consequences of liquid transfusion. Th  ey 
have been very successful in managing these issues. 
However, there have been very few well designed studies 
over the past 30 years in the transfusion literature 
describ  ing any clinical improvements after transfusion in 
trauma patients. No quality data from studies in trauma 
patients are available for current blood products. 
Amazingly, there is no requirement to have clinical 
outcome data when modiﬁ  cations to currently approved 
blood products are introduced. Injury has been recog-
nized as causing more than 5 million deaths worldwide 
and is listed as a major global issue by the WHO [7]. It is 
time for blood banks to evolve [8]. It is easy to anticipate 
a separation of emergency transfusion in rapidly bleeding 
patients from the traditional blood bank over the next 
decade, with dried blood products/proteins utilized in a 
point of care mode, stored in the clinical areas where the 
patients are cared for (including the pre-hospital environ-
ment), and resuscitation based upon laboratory data 
available within minutes that guide protein-speciﬁ  c 
infusion. It will be nice to only transfuse what is needed, 
based on level I data, ﬁ  nally balancing risk and beneﬁ  t in 
a data-driven fashion for the beneﬁ  t of our patients. Th  e 
paper by Schochl and colleagues is a step in that 
direction.
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